Co-Authors
This is a "connection" page, showing publications co-authored by Fabio Ciceri and Giulio Cavalli.
Connection Strength
1.135
-
Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. Lancet Rheumatol. 2021 Apr; 3(4):e253-e261.
Score: 0.232
-
Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med. 2020 06; 76:43-49.
Score: 0.221
-
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020 Jun; 2(6):e325-e331.
Score: 0.220
-
A virus-free cellular model recapitulates several features of severe COVID-19. Sci Rep. 2021 09 01; 11(1):17473.
Score: 0.060
-
Testosterone in males with COVID-19: A 7-month cohort study. Andrology. 2022 01; 10(1):34-41.
Score: 0.060
-
Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation. Front Immunol. 2021; 12:675678.
Score: 0.059
-
Correction to: Can Cytokine Blocking Prevent Depression in COVID-19 Survivors? J Neuroimmune Pharmacol. 2021 Mar; 16(1):211.
Score: 0.058
-
Can Cytokine Blocking Prevent Depression in COVID-19 Survivors? J Neuroimmune Pharmacol. 2021 03; 16(1):1-3.
Score: 0.057
-
Targeting IL-1, IL-6 or GM-CSF in COVID-19. Response to: 'More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia' by Ferraccioli. Ann Rheum Dis. 2020 Jul 31.
Score: 0.056
-
Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Ann Rheum Dis. 2020 10; 79(10):1277-1285.
Score: 0.056
-
GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. Lancet Rheumatol. 2020 Aug; 2(8):e465-e473.
Score: 0.055